{"id":"NCT03036124","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure","officialTitle":"Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-08","primaryCompletion":"2019-07-17","completion":"2019-07-17","firstPosted":"2017-01-30","resultsPosted":"2020-09-01","lastUpdate":"2020-09-01"},"enrollment":4744,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Forxiga TM","Farxiga TM"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction","primaryOutcome":{"measure":"Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.","timeFrame":"Up to 27.8 months.","effectByArm":[{"arm":"Dapa 10 mg","deltaMin":386,"sd":null},{"arm":"Placebo","deltaMin":502,"sd":null}],"pValues":[{"comp":"OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":419,"countries":["United States","Argentina","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Germany","Hungary","India","Japan","Netherlands","Poland","Russia","Slovakia","Sweden","Taiwan","United Kingdom","Vietnam"]},"refs":{"pmids":["40465275","40088234","38770818","38537918","38320525","37886880","37407113","37318419","37220172","37211977","37210608","37039015","36881399","36811901","36592046","36339117","36189985","36054568","35971840","35902157","35483792","35467935","35442064","35115084","34969498","34861151","34802253","34743554","34448003","34319398","34272791","33832352","33787831","33595593","33549554","33368858","33355302","33164553","33082245","33040613","32883108","32820334","32673497","32653447","32539224","32219386","31736335","31736328","31535829","31309699","31081589"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1699C00001&amp;attachmentIdentifier=66b47cad-8320-450c-8663-8298a1e7f535&amp;fileName=D1699C00001_Protocol_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1699C00001&amp;attachmentIdentifier=0dea388e-44d4-4c23-9555-8aea2ea3448d&amp;fileName=D1699C00001_Statistical_Analysis_Plan_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":895,"n":2368},"commonTop":["Cardiac failure","Hypotension","Nasopharyngitis","Renal impairment","Atrial fibrillation"]}}